title: Effect of interferon-alpha on immunoglobulin production by peripheral blood mononuclear cells in multiple myeloma.
abstract: To test a hypothesis that interferon-alpha (IFN) treatment might restore normal immunoglobulin (Ig) production in multiple myeloma (MM), the effect of IFN on Ig isotype (IgG and IgA) production by peripheral blood (PB) and bone marrow (BM) mononuclear cells (MNCs) in MM patients was analyzed by ELISA. IFN at a concentration of 1000 U/ml was found to enhance IgA production by PB MNCs in IgA-MM and had a trend to stimulate IgG production in IgG-MM. The effect of IFN on nonparaprotein Ig isotype production was more variable, with mostly neutral or inhibitory effects being seen in both the MM subtypes. In contrast to the influences observed in MM patients, IFN at the same concentration inhibited both IgG and IgA production by PB MNCs in healthy controls. In studying BM cells, IFN was found to reduce IgA production in IgA-MM, but had a neutral effect on IgG production in IgG-MM. In the controls, the production of both the IgG and the IgA isotypes by BM MNCs was decreased by IFN. On the basis of these results it seems that the disease itself somehow affects the Ig-producing cells in MM, when measured as different responses of the cells to exogenous IFN in vitro. The results do not support the hypothesis that IFN treatment could restore normal Ig production in MM patients.
authors.affiliation: Department of Clinical Chemistry, University of Oulu, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Säily
authors.forename: P
authors.initials: P
authors.lastname: Koistinen
authors.forename: S
authors.initials: S
authors.lastname: Laine
authors.forename: E
authors.initials: E
authors.lastname: Soppi
authors.forename: E R
authors.initials: ER
authors.lastname: Savolainen
mesh_terms: D000328:Adult; D000368:Aged; D000917:Antibody Formation / Q000187:drug effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D001853:Bone Marrow / Q000473:pathology; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use; D007370:Interferon Type I / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000276:immunology / Q000628:therapy*; D009194:Myeloma Proteins / Q000096:biosynthesis; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000276:immunology; D010950:Plasma Cells / Q000187:drug effects* / Q000276:immunology; D011994:Recombinant Proteins; D017211:Treatment Failure
chemical_list: D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007155:Immunologic Factors; D007370:Interferon Type I; D009194:Myeloma Proteins; D011994:Recombinant Proteins